EcoR1 Capital’s Aktis Oncology AKTS Stock Holding History

EcoR1 Capital’s Portfolio AKTS Stock Details AKTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$155M	Hold	4,824,469	–	–	7.56%	3
2026 Q1	$86.3M	Buy	+4,824,469	New	+$93.7M	3.66%	6

Other funds holding AKTS

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

EcoR1 Capital's AKTS Position: Q2 2026 in Review

EcoR1 Capital held its Aktis Oncology (AKTS) position steady in Q2 2026 at 4,824,469 shares worth $155M. The position accounts for 7.56% of the portfolio, ranked #3.

EcoR1 Capital first reported a position in AKTS in Q1 2026 and has held it in 2 quarters since. 114 funds tracked by Wall St. Rank hold AKTS as of Q2 2026.

EcoR1 Capital held 4,824,469 shares of Aktis Oncology worth $155M as of Q2 2026.
EcoR1 Capital left its Aktis Oncology share count unchanged in Q2 2026.
Aktis Oncology made up 7.56% of EcoR1 Capital's portfolio in Q2 2026, its #3 holding.
EcoR1 Capital first reported a position in Aktis Oncology in Q1 2026 and has held it in 2 quarters since.
114 funds tracked by Wall St. Rank held Aktis Oncology as of Q2 2026.

Based on EcoR1 Capital's 13F filing for Q2 2026, filed 14 Aug 2026.